Can females get Merkel cell carcinoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Females Get Merkel Cell Carcinoma?

Yes, females can definitely get Merkel cell carcinoma (MCC), although it is more common in older white men. 1

Epidemiology and Risk Factors

Merkel cell carcinoma affects both males and females, with the following characteristics:

  • More common in males than females, but both sexes can develop the disease
  • Predominantly affects older individuals (≥65 years of age)
  • Occurs primarily in Caucasians (≥95% of cases)
  • Risk factors that apply to both sexes include:
    • Extensive sun exposure (major risk factor)
    • Advanced age (>90% of patients are over 50 years, >76% are ≥65 years)
    • Immunosuppression (organ transplants, lymphoproliferative malignancies, HIV infection)
    • Merkel cell polyomavirus (MCPyV) infection (detected in 43-100% of tumors)

Clinical Presentation

MCC presents similarly in both males and females:

  • Typically appears as a rapidly growing, asymptomatic lesion
  • Most commonly occurs on sun-exposed areas (81% of cases)
  • Head and neck are common locations (29-48% of all primary MCCs)
  • Appears as a red nodule or plaque with fast growth
  • Rarely clinically suspected due to lack of distinguishing features

Diagnosis

The diagnostic approach is identical for both sexes:

  • Complete examination of skin and lymph nodes
  • Biopsy of suspicious lesion
  • Histopathologic examination showing small-cell neuroendocrine appearance
  • Immunohistochemistry showing CK20 positivity and TTF-1 negativity
  • Imaging studies to rule out regional and distant metastases

Treatment Considerations

Treatment protocols do not differ based on sex:

  1. For localized disease:

    • Surgical excision with postoperative margin assessment
    • Sentinel lymph node biopsy
    • Adjuvant radiation therapy
  2. For advanced disease:

    • Immunotherapy with anti-PD-(L)1 antibodies as first-line systemic treatment
    • Chemotherapy for patients who fail to respond to immunotherapy

Prognosis

MCC is aggressive in both males and females:

  • High mortality rate exceeding that of melanoma
  • 5-year overall survival rates range from 30% to 64%
  • Recurrence develops in 25-50% of all cases
  • Local recurrence in 25-30% of cases
  • Regional disease in 52-59% of cases
  • Distant metastatic disease in 34-36% of cases

Important Considerations

  • Early detection is crucial regardless of sex
  • Regular skin examinations are recommended for high-risk individuals
  • Immunosuppressed patients of both sexes require closer monitoring due to higher risk
  • Expeditious initiation of treatment is recommended for all patients

MCC is a rare but aggressive skin cancer that can affect both males and females, with a predilection for older, fair-skinned individuals with significant sun exposure history.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.